AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05589012 — intervention group
Intervention type: BIOLOGICAL
Intervention: Cell line and virus
Description: C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.
Study NCT05589012 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infection of human placental culture explants
Description: Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots.~Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air.
Study NCT05589012 — intervention group
Intervention type: BIOLOGICAL
Intervention: Determination of viral load in tissues by qRT-PCR
Description: The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions.~Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV.
Study NCT06373900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wound closure
Description: Group A wound will be closed with Polypropylene and Group B wound will be closed with Polyglactin 910 suture. both wound closure followed for healing, infection and scar formation till 30th post operative day.
Study NCT06301776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: To compare the safety and efficacy of different DAPT duration combined with ticagrelor monotherapy.
Study NCT06301776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: To compare the safety and efficacy of different DAPT duration combined with ticagrelor monotherapy.
Study NCT05453071 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Exercise Therapy Approach (BETY)
Description: BETY, based on function-oriented core stabilization exercises, will be applied in patients with systemic sclerosis. This exercise model includes pain management strategies, dance therapy-authentic movement. Function-oriented core stabilization exercises have the feature of being made difficult against gravity according to the person's ability to do. Initial exercises start from the stage where the distal segment of the extremity is on the ground, called closed-kinetic. This level, which is quite easy, becomes more difficult following the success of the individual. It can be started from the mat level and progressed by modifying it with theraband and exercise ball. It is used at the beginning and end of dance therapy and authentic movement sessions. In the session, cognitive restructuring technique is used to break the vicious cycle of pain-emotional-spasm during exercise. This exercise model is the main rehabilitation approach of the Rheumatological Rehabilitation Unit.
Study NCT05687253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BX1000
Description: IV BX1000
Study NCT05687253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium Bromide
Description: IV Rocuronium
Study NCT06104670 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
Study NCT04178434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based CBT intervention
Description: A nine step intervention including internet-based feedback by psychologists
Study NCT04851327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Energy preload
Description: Tests the extent to which participants reduce their intake at a meal following ingestion of a high energy preload drink
Study NCT04851327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low energy preload
Description: Tests the amount participants eat at a meal following ingestion of a low energy preload drink
Study NCT04851327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Test meal to follow low or high energy preload
Study NCT05399160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Supportive Care
Description: Nurse-led supportive care was given to women who had breast surgery and planned to receive chemotherapy. Nurse-led supportive care was applied to women for eight weeks in the form of face-to-face clinic and telephone interviews.It took an average of 30 minutes to interview women with breast cancer at the clinic, and 15 minutes on average by phone.
Study NCT06227572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CATNAP MI
Description: Three motivational interviewing (MI) sessions will be facilitated by trained MI staff and will focus on improving participants' knowledge about their OSA diagnosis, understanding of sleep health, and increasing PAP use. Sessions will also provide information about health benefits associated with good sleep and will help participants create an action plan regarding their PAP use and indicators of success, when appropriate.~Electronic messaging will be standardized for frequency and content but personalized to participants' preferred mode of delivery. Messages will focus on PAP adherence or non-adherence.
Study NCT05708729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCS surgery for CPSP
Description: The investigational devices that will be used for the MCS surgeries are the following: the Vanta with AdaptiveStim Technology Primary cell neurostimulator or the Intellis Implantable Neurostimulator with AdaptiveStim Technology from Medtronic, Inc. (MN, USA). These implantable neurostimulators are intended to generate electrical pulses and to deliver stimulation trough one or more leads as part of a neurostimulation system for pain therapy in adults.
Study NCT05708729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vc-DBS surgery for CPSP
Description: For the deep brain stimulation procedure, we will use Vercise stimulators from Boston Scientific together with the Cartesia Directional Leads or the Percept PC stimulator from Medtronic.
Study NCT05214105 — intervention group
Intervention type: OTHER
Intervention: Biospecimen/DNA collection and analysis
Description: Patients will be followed longitudinally with collection of CBC and chemistries as well as research biomarkers (urine, plasma, and genomic materials).
Study NCT04953936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB-enriched Nutritional Supplements
Description: The participants will receive oral HMB-enriched nutritional supplements (65 g, once daily), which include soybean isolate protein, flaxseed oil powder, yam powder, whey protein, oligomeric isomaltose powder, cocoa powder, medium-chain fatty acid powder, calcium beta-hydroxy-beta-methylbutyrate, sunflower seed oil powder, L-glutamine, wheat germ powder, membrane isolated casein, wheat oligopeptide, konjac flour, vitamin E, vitamin D, stevioside, edible flavors.
Study NCT04953936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (maltodextrin 65 g once daily) with the same package as the intervention.
Study NCT04953936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restrition Diet
Description: Caloric restriction diet with individualized nutritional guidance from professional dietitians by video regarding caloric restriction strategies
Study NCT04953936 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Caloric Restrition Diet
Description: Caloric restriction diet with individualized nutritional guidance from professional dietitians by video regarding caloric restriction strategies
Study NCT05300620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Foot Orthotics EVA
Description: these are custom foot orthotics made out of Ethyl Vinyl Acetate material
Study NCT05300620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Original Liner
Description: these are original shoe liners
Study NCT05300620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Foot Orthotics PU
Description: these are custom foot orthotics made out of Expanded Poly Urethane Material
Study NCT05300620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Hybrid Foot Orthotics
Description: these are custom foot orthotics made out of a combination of Ethyl Vinyl Acetate and Expanded Poly Urethane Material
Study NCT05021991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PRAX-944
Description: Once daily oral treatment with titration
Study NCT05021991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100 mg PRAX-944
Description: Once daily oral treatment with titration
Study NCT05021991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg PRAX-944
Description: Once daily oral treatment with titration
Study NCT05021991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 60 mg PRAX-944
Description: Once daily oral treatment with titration
Study NCT05021991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily oral treatment
Study NCT05021991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily oral treatment
Study NCT05021991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flexibly dosed 20 mg to 100 mg PRAX-944
Description: Once daily oral treatment
Study NCT05021991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flexibly dosed 20 mg to 100 mg PRAX-944
Description: Once daily oral treatment
Study NCT05163444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait analysis with rolling cane
Description: 6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
Study NCT05163444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gait analysis with quadripod cane
Description: 6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
Study NCT06011057 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum C reactive protein (CRP) level
Description: An immunoturbidimetric method using a Modular P Analyzer will be used to carry out HSCRP assay, with a quantitation limit of 0.5 mg/L.
Study NCT06011057 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: All examinations will be carried out by an experience operator with a transvaginal probe on high-resolution ultrasound machines. Pregnancies will be dated from the LMP. Other measurements will be obtained during the scan as the mean gestation sac diameter, volume of the gestation sac and the embryonic heart rate (FHR).
Study NCT05577442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy
Description: Trastuzumab (8-6mg/3weekly)，Pyrotinib（320mg/day）Dalpiciclib（125mg/day，With three weeks separated by one week）
Study NCT06025097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Solution
Description: Methyl Prednisone (Trade name: SOLU-MEDROL) + Platelet rich Plasma (Autologous Biological product) via intra-tympanic rout about 1-1.5 ml.
Study NCT06364098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 microgram of misoprostol given either sublingually or intrauterine during CS after placental removal together with IV oxytocin infusion
Study NCT06364098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 microgram of misoprostol given either sublingually or intrauterine during CS after placental removal together with IV oxytocin infusion
Study NCT04807790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation based structured home program applications
Description: The structured home program will consist of activities determined by the family members according to the functional level of the child and the activities he / she can not do, and which are determined according to the goals specific to the child. In order to ensure that the structured home program created can be implemented by the family, a 1 hour family training will be provided.~After the structured home program training, a 45-minute video interview will be held with one of the family members (mother-father-caregiver) once a week, in order to check by the physiotherapist whether the home program is implemented correctly. Video interviews will be the telerehabilitation part of the study.
Study NCT05315973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testing sensor vs glucometer
Description: Will test accuracy of this sensor; there will be no intervention.
Study NCT05135182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: Furazolidone-tetracycline-containing quadruple regimens
Study NCT05135182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: metronidazole-tetracycline-containing quadruple regimens
Study NCT05933993 — intervention group
Intervention type: OTHER
Intervention: Elective cesarean section
Description: The study does not contain an intervention in itself, but women are included if they undergo an elective cesarean section
Study NCT05894486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium[177Lu] Oxodotreotide Injection
Description: Lutetium\[177Lu\] Oxodotreotide InjectionFour administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity
Study NCT06000800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B
Description: Umbilical cord clamping at 30 seconds
Study NCT06000800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group C
Description: Umbilical cord clamping at 60 seconds
Study NCT06000800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group D
Description: Umbilical cord clamping at 90 seconds
Study NCT06000800 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: Umbilical cord clamping immediately after birth (5 second)
Study NCT05381532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled sleep
Description: Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment.
Study NCT06257615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education provided via TeleNursing
Description: Online Video Call Online video interviews were conducted with the patients in the intervention group once in the first week (day 1-7), once in the second week (day 8-14) and once in the third week, using mobile phone programs and/or computer programs that provide video conversation opportunities. It was conducted in the form of remote online video calls, held three times in total, once within the 15-21st day.~Voice Phone Call After audio telephone interviews and online video interviews were completed within the first three weeks after the patients in the intervention group were discharged; It was carried out using a mobile phone 3 times in total: once in the fourth week (day 22-28), once in the fifth week (day 29-35) and once in the sixth week (day 36-42).
Study NCT05916144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interaction-Based Early Education Program
Description: The intervention program will be created based on the ETEÇOM model which is the Turkish adaptation of the Responsive Teaching Program developed in the United States. In this program, by improving the interactive behaviors of experts/educators or parents, the aim is for the child to acquire or develop 15 core behavior. Each session is planned to last between 60-90 minutes on average and will be conducted in a group format, consisting of 5 sessions, and can be conducted face-to-face or online.
Study NCT06196814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy
Description: PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
Study NCT05092997 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: POC viral load testing
Description: POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL >200 c/ml will receive additional adherence counseling, following the STREAM protocol, \[26\] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
Study NCT05092997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness visit services for male partners
Description: Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
Study NCT05104320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MICS-CABG
Description: Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.
Study NCT05104320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sternotomy CABG
Description: Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
Study NCT04847362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: education group
Study NCT05083572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colonic lavage with polyethylene glycol
Description: The subjects will orally consume a split dose of bowel preparation (PEG); 2 litres in the evening (Day -1) and another 2 litres the following morning (Day 1).
Study NCT05083572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The subjects will self-administer orally two capsules of Vivomixx with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.
Study NCT05083572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: The subjects will undergo pre-treatment to cleanse the gut by consuming orally one tablet of antibiotic rifaximin (200mg) daily for 14 days prior to the initiation of Vivomixx course.
Study NCT06229340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: 100 mg daily for 3 days at the loading dose, then 20 mg daily at the standard dose.
Study NCT06229340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab
Description: Use of one of the possible MEK-inhibitor options:~Trametinib 2 mg once daily orally; Cobimetinib 60 mg on days 1-21, break 7 days, cycle 28 days orally; Binimetinib 45 mg 2 times a day daily orally. + Hydroxychloroquine 600 mg 2 times a day daily orally.~± Bevacizumab 7.5 mg/m² every 3 weeks intravenously.
Study NCT05136768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg, administered by intravenous infusion on the first day of each cycle, one cycle every 3 weeks (Q3W), with the maximum cycle of 17. Suspension of Sintilimab administration: patients's request, disease progression, researcher-evaluated SAE
Study NCT05136768 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: At least one metastatic lesion is suitable for SBRT. If applicable, all metastatic lesions were allowed to be irradiated.~Recommended dose: BED ≥ 80Gy. Dose fractionation is determined as per physician's discretion, generally depending on the location of irradiated lesion and the distance to surrounding OARs.~Timing of SBRT: After completing at least 2 platinum-containing chemotherapy plus sintilimab treatments, SBRT can be started after assessing that there is no AE ≥ G2.
Study NCT05136768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: Platinum based single or doublet chemotherapy, one cycle every 3 weeks (Q3W), 4-6 cycles.
Study NCT05213650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-abrasive toothpaste
Description: Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Non-abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.